A Phase I/II Open-Label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer in China
Latest Information Update: 16 Apr 2025
At a glance
- Drugs HP 518 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hinova pharmaceuticals
- 13 Apr 2025 Planned number of patients changed from 62 to 84.
- 13 Apr 2025 Planned primary completion date changed from 1 Jul 2026 to 1 Oct 2025.
- 18 Mar 2024 Status changed from not yet recruiting to recruiting.